Cervical cancer PD-L1 testing for KEYTRUDA® (pembrolizumab)
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
PDF, 1.83 MB
KEYTRUDA in combination with chemotherapy, with or without bevacizumab, is indicated for the treatment of persistent, recurrent or metastatic cervical cancer in adults whose tumours express PD‑L1 CPS ≥1.
CPS = Combined Positive Score; PD-L1 = Programmed Death Ligand 1
More information about KEYTRUDA® (pembrolizumab) in cervical cancer
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website